TY - JOUR
T1 - Carbocalcitonin (Turbocalcin* * Carbocalcitonin - Turbocalcin
T2 - ISF, Italy.) treatment of Paget's disease and osteoporosis. Preliminary results
AU - Mantovani, G.
AU - Pastore, U.
AU - Varriale, E.
AU - Cerea, P.
AU - Ulivi, M.
AU - Bonfiglio, G.
AU - Torri, G.
AU - Pietrogrande, V.
PY - 1986
Y1 - 1986
N2 - A study of Paget's disease patients, classed as non-responders to other calcitonins, and of high-turnover osteoporotic patients is presented. In these two groups of patients evaluation was made of the clinical and metabolic changes produced by carbocalcitonin therapy over a relatively short time period, corresponding to 30 days in the case of Paget's disease patients and 60 days in the case of osteoporotic patients. After treatment with 40 units of carbocalcitonin the changes observed in alkaline phosphatase and urinary hydroxyproline respectively are described. Trends of different significance were observed for Paget's disease patients and osteoporotic patients. The pain parameter showed positive changes in both groups. Different pathogenic hypotheses are postulated in the light of these results.
AB - A study of Paget's disease patients, classed as non-responders to other calcitonins, and of high-turnover osteoporotic patients is presented. In these two groups of patients evaluation was made of the clinical and metabolic changes produced by carbocalcitonin therapy over a relatively short time period, corresponding to 30 days in the case of Paget's disease patients and 60 days in the case of osteoporotic patients. After treatment with 40 units of carbocalcitonin the changes observed in alkaline phosphatase and urinary hydroxyproline respectively are described. Trends of different significance were observed for Paget's disease patients and osteoporotic patients. The pain parameter showed positive changes in both groups. Different pathogenic hypotheses are postulated in the light of these results.
KW - alkaline phosphatase
KW - carbocalcitonin
KW - osteoporosis
KW - Paget's bone disease
KW - urinary hydroxyproline
UR - http://www.scopus.com/inward/record.url?scp=0022904945&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022904945&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0022904945
VL - 23
SP - 109
EP - 117
JO - Clinical Trials Journal
JF - Clinical Trials Journal
SN - 0009-9325
IS - SUPPL. 1
ER -